In this cohort study involving 56 patients with metastatic melanoma, researchers sought to assess the risk of a recurrence of immune toxic effects correlated with anti-programmed cell death 1 antibody (anti–PD-1) therapy after discontinuation of ipilimumab monotherapy due to severe adverse events (AEs).
Publications
Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma
Given that significantly longer relapse-free survival with 12 months of adjuvant dabrafenib plus trametinib vs placebo in patients with resected stage III melanoma with BRAF V600E or V600K mutations has been reported in the earlier reported primary analysis of this phase 3 trial, researchers undertook this investigation to corroborate the stability of the relapse-free survival benefit.
Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018
Researchers reviewed the prescribing of first?line checkpoint inhibitors (CPIs) for the treatment of patients with metastatic melanoma in England since their introduction in 2014 to better understand the clinical practice and used national databases to link outcomes such as survival and treatment toxicity of treated patients.
Predictors of long-term anxiety and depression in uveal melanoma survivors: A cross-lagged five-year analysis
Data were obtained from sample of 453 uveal melanoma survivors who completed observations 6?, 12?, 24?, 36?, 48? and 60?months postdiagnosis and missed no two consecutive observations.